While I expect the status quo to continue in 2020 regarding drug price reform, as the end of the year approaches there will be considerable uneasiness in the pharmaceutical and health insurance industries about imminent changes in 2021 and 2022.
While I expect the status quo to continue in 2020 regarding drug price reform, as the end of the year approaches there will be considerable uneasiness in the pharmaceutical and health insurance industries about imminent changes in 2021 and 2022.